|
��չ����
|
|
| ������Ϣ | |
 |
Supporting info |
|
PDFȫ�� |
|
[HTMLȫ��] |
|
����� |
| �����뷴�� | |
|
�������ù����� |
|
���� |
|
Email Alert |
|
���·��� |
|
���������Ϣ |
| ���Ĺؼ���������� | |
|
���Ī�� |
|
����ҽѧ�о� |
|
�������� |
| ��������������� | |
|
��־�� |
|
���� |
|
���� |
| PubMed | |
|
Article by LI Zhi-jun |
|
Article by LIU Liu |
|
Article by HE Li |
�������Ī�ص��о���չ
��־��1, ����1, ����2
1. ����ҽѧԺ��һ����ҽԺ��ǻ������ 650032;
2. ����ҽѧԺ��һ����ҽԺƤ����
���Ī��Ϊ�Ǻ����ӻ���С�������ߵ��ڼ�,��ΪToll������7��Ч��,ͨ���յ���������������ء��������������ӡ�����-12��ϸ������,�̼���������ϵͳʶ����Ⱦ����������,����������ز����ڹ����ѹ㷺�������Ƹ�������ֳ���ࡢ�չ��Խǻ�����dz���Ի���ϸ�������������о��IJ�������,��Ӧ֤Ҳ��������,��ʾ����Ƥ�����������Ÿ�������Ӧ��ǰ����
Progress in the Research of Topical Imiquimod
Department of Oral and Maxillofacial Surgery, First Affiliated Hospital of Kunming Medical College, Kunming 650032, China
Department of Oral and Maxillofacial Surgery, First Affiliated Hospital of Kunming Medical College, Kunming 650032, China
Imiquimod, a small-molecule of non-nucleotide and heterocyclic amine, also an immune response modifier of the imidazoquinoline family members, has been widely used in anal and external genital warts, actinic keratosis and superficial basal cell carcinoma in abroad. As an agonist of Toll-like receptors, iteliminates the lesions by inducing the production of cytokines (IFN-��, TNF-��, IL-12,etc)and stimulating the recognition of viral infection and tumors by the immune system. The clinical application and progress of it are reviewed here. With the development of the research and realization of its mechanisms, its indications will increase, and it will have a more prospective application in dermatology.
[2] Vidal D,Matias-Guiu X,Alomar A.Efficacy of imiquimod for the expression of Bcl-2,Ki67,p53 and basal cell carcinoma apoptosis.Br J Dermatol,2004,151:656-662.
[3] Peris K,Campione E,Micantonio T,et al.Imiquimod treatment of superficial and nodular basal cell carcinoma:12-week open-label trial.Dermatol Surg,2005,31:318-323.
[4] Smith K J,Hamza S,Skelton H.Topical imidazoquinoline therapy of cutaneous squamous cell carcinoma polarizes lymphoid and monocyte/macrophage populations to a Thl and M1 cytokine pattern.Clin Exp Dermatol,2004,29:505-512.
[5] Martin-Garcia RF.Imiquimod:an effective alternative for the treatment of invasive cutaneous squamous cell carcinoma.Dermatol Surg,2005,31:371-374.
[6] Wolf IH,Cerroni L,Kodama K,et al.Treatment of lentigo maligna (melanoma in situ) with the immune response modifier imiquimod.Arch Dermatol,2005,141:510-514.
[7] Kamin A,Eigentler TK,Radny P,et al.Imiquimod in the treatment of extensive recurrent lentigo maligna.J Am Acad Dermatol,2005,52(2 Suppl 1):51-52.
[8] Schon MP,Wienrich BG,Drewniok C,et al.Death receptor-independent apoptosis in malignant melanoma induced by the small-molecule immune response modifier imiquimod.J Invest Dermatol,2004,122:1266-1276.
[9] Hesling C,D' Incan M,Mansard S,et al.In vivo and in situ modulation of the expression of genes involved in metastasis and angiogenesis in a patient treated with topical imiquimod for melanoma skin metastases.Br J Dermatol,2004,150:761-767.
[10] Hazen PG,CarneyJF,Engstrom CW,et al.Proliferating hemangioma of infancy:successful treatment with topical 5% imiquimod cream.Pediatr Dermatol,2005,22:254-256.
[11] Welsh O,Olazaran Z,Gomez M,et al.Treatment of infantile hemangiomas with short-term application of imiquimod 5% cream.J Am Acad Dermatol,2004,51:639-642.
[12] Martinez MI,Sanchez-Carpintero I,North PE,et al.Infantile hemangioma:clinical resolution with 5% imiquimod cream.Arch Dermatol,2002,138:881-884.
[13] Sidbury R,Neuschler N,Neuschler E,et al.Topically applied imiquimod inhibits vascular tumor growth in vivo.J Invest Dermatol,2003,121:1205-1209.
[14] Clejan S,Mandrea E,Pandrea ��,et al.Immune responses induced by intranasal imiquimod and implications for therapeutics in rhinovirus infections.J Cell Mol Med,2005,9:457-461.
[15] Korman N,Moy R,Ling M,et al.Dosing with 5% imiquimod cream 3 times per week for the treatment of actinic keratosis:results of two phase 3,randomized,double-blind,parallel-group,vehicle-controlled trials.Arch Dermatol,2005,141:467-473.
[16] Szeimies RM,Gerritsen MJ,Gupta G,et al.Imiquimod 5% cream for the treatment of actinic keratosis:results from a phase ��,randomized,double-blind,vehicle-controlled,clinical trial with histology.J Am Acad Dermatol,2004,51:547-555.
[17] Bianchi L,Campione E,Marulli GC,et al.Actinic keratosis treated with an immune response modifier:a case report of six patients.Clin Exp Dermatol,2003,28(Suppl 1):39-41.
[18] Lysa B,Tartler U,WolfR,et al.Gene expression in actinic keratoses:pharmacological modulation by imiquimod.Br J Dermatol,2004,151:1150-1159.
[19] Jacob SE,Berman B,Nassiri M,et al.Topical application of imiquimod 5% cream to keloids alters expression genes associated with apoptosis.Br J Dermatol,2003,149(Supp166):62-65.
[20] Berman B,Villa A.Imiquimod 5% cream for keloid management.Dermatol Surg,2003,29:1050-1051.
[21] Prado A,Andrades P,Benitez S,et al.Scar management after breast surgery:preliminary results of a prospective,randomized,and double-blind clinical study with aldara cream 5% (imiquimod).Plast Reconstr Surg,2005,115:966-972.